Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Florence, Italy; Cardiomyopathy Unit, University Hospital of Careggi, Florence, Italy. Electronic address: niccolo.maurizi@gmail.com.
² Cardiomyopathy Unit, University Hospital of Careggi, Florence, Italy.
³ Arcard Foundation, Florence, Italy.

Comment

Niccolò Maurizi et al. Int J Cardiol. 2017.

. 2017 Nov 1:246:55.

doi: 10.1016/j.ijcard.2017.03.107.

¹ Department of Clinical and Experimental Medicine, University of Florence, Italy; Cardiomyopathy Unit, University Hospital of Careggi, Florence, Italy. Electronic address: niccolo.maurizi@gmail.com.
² Cardiomyopathy Unit, University Hospital of Careggi, Florence, Italy.
³ Arcard Foundation, Florence, Italy.

No abstract available

Comment on

Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
Maurizi N, Tanini I, Olivotto I, Amendola E, Limongelli G, Losi MA, Allocca G, Perego GB, Pieragnoli P, Ricciardi G, De Filippo P, Ferrari P, Quarta G, Viani S, Rapacciuolo A, Bongiorni MG, Cecchi F. Maurizi N, et al. Int J Cardiol. 2017 Mar 15;231:115-119. doi: 10.1016/j.ijcard.2016.12.187. Epub 2017 Jan 4. Int J Cardiol. 2017. PMID: 28073660
Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?
Qin F, Liu Q, Liu Z. Qin F, et al. Int J Cardiol. 2017 Nov 1;246:54. doi: 10.1016/j.ijcard.2017.03.016. Int J Cardiol. 2017. PMID: 28867015 No abstract available.